5,623 reports of this reaction
1.8% of all ADALIMUMAB ADAZ reports
#6 most reported adverse reaction
ARTHRALGIA is the #6 most commonly reported adverse reaction for ADALIMUMAB ADAZ, manufactured by Cordavis Limited. There are 5,623 FDA adverse event reports linking ADALIMUMAB ADAZ to ARTHRALGIA. This represents approximately 1.8% of all 305,491 adverse event reports for this drug.
Patients taking ADALIMUMAB ADAZ who experience arthralgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ARTHRALGIA is a less commonly reported adverse event for ADALIMUMAB ADAZ, but still significant enough to appear in the safety profile.
In addition to arthralgia, the following adverse reactions have been reported for ADALIMUMAB ADAZ:
The following drugs have also been linked to arthralgia in FDA adverse event reports:
ARTHRALGIA has been reported as an adverse event in 5,623 FDA reports for ADALIMUMAB ADAZ. This does not prove causation, but indicates an association observed in post-market surveillance data.
ARTHRALGIA accounts for approximately 1.8% of all adverse event reports for ADALIMUMAB ADAZ, making it a notable side effect.
If you experience arthralgia while taking ADALIMUMAB ADAZ, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.